The pathology reports and operative findings were used to determine: the principal tumor size, number of lesions, lobar distribution, vascular and lymphatic tumor extension, surgical margins, distant metastases, and the presence or absence of associated cirrhosis. When available, the tumor markers were recorded as well as the virus markers (hepatitis C virus, hepatitis B virus).
Staging was with the pTNM classification proposed by the International Union Against Cancer and the American Joint Committee on Cancer. 18.19 Thirty-seven of the 41 patients had stage IV tumors at the time of surgery (Table 1) .
Surgical Procedures
Partial hepatectomy (PH x) was the procedure of choice. Total hepatectomy (THx) and OLT were performed when tumor extension or the presence of underlying liver disease precluded PHx. Both PHx and THx were frequently performed under highly unfavorable conditions, such as lymph node involvement and/or direct invasion of tumor into the adjacent organs· Sublolal Hepatectomy (PHx). In 8 of the 28 patients. resection included one or more surrounding organs in an attempt 10 secure tumor-free margins. The types of PHx performed in this group are summarized in Table 2 , using surgical techniques that have been described elsewhere 2o . 11 THx and OLT. In 6 of these 13 patients, the THx was extended to adjacent organs (Table 2) . Two patients had upper abdommal exenteration and organ cluster transplantatlon. 2UJ In 1 patient, Ol T was combined with pancreaticoduodenectomy (Whipple procedure). The surgIcal techmques for Oll and the immunosuppression used thereafter have been described elsewhere. 22 . 1h Immunosuppression was with cyclosporine and prednisone (n = 9), imuran and prednisone In == I), or tacrolimus and prednisone (n = 3). 
Adjuvant Therapy
Sixteen patients received adjuvant radiotherapy or chemotherapy before and/or after surgery (Table 3) . These regimens were highly variable in the long period of the study. Adriamycin ::!: Cis-Platinum were most commonly used.
Statistical Analysis
Cumulative overall survivals and tumor-free survivals were calculated by the method of Kaplan-Meier with adjustment for types of surgery (OLT vs. PHX). 27 Potential risk factors studied by univariate analvsis were tumor size, number of lesions, lobar involvement, vasc~lar invasion, lymph node invasion. distant metastases, pTNM stage, surgical margins, and adjuvant chemotherapy. P < .05 was considered significant. The small number of patients with different potential risk factors precluded multivariate analysis.
RESULTS

Pathological Characteristics
Tumor Size. Number, and Lobar Distribution. The principal tumors had a median diameter of 13 cm (mean::!: SD = 12.4 ::!: 4.3 em) with a range between 3 to 25 cm. Thirty patients (73°1.1) had a single tumor. The remaining 11 patients (27%) had two or more lesions. The tumor(s) was bilobar in 30 patients (73%). The tumor(s) involved only the left lobe in 7 patients and the right lobe in 4 (Tables + and 5). OLT + pylorus + omentum resect. (n = 1)
OLT + Whipple procedure (n = 1)
OLT + cluster resection (n = 2) NOTE. n = 41. (Tables 4 and 5) . Metastases. Thirteen patients (31.7%) had regional metastatic disease (Ml) at the time of surgery (Tables 4 and 5) , which was resected in continuity with the principal tumor (Table 6) .
Cirrhosis, Tumor Markers, and Serology. Three patients in the OLT group had associated cirrhosis (7.3%). One of these patients is alive 120 months after OLT, 1 died with tumor recurrence at 25 months, and the third patient died at 66 months with tumor recurrence.
Nineteen patients were tested for a-fetoprotein, with only 2 00.5%) elevations. However, all of the 10 patients tested for Des-y-carboxy prothrombin 2H had elevated serum levels despite normal levels of a-fetoprotem.
Of the 30 patients tested for hepalltis B virus, none had a positive serology. The positive rate for hepatitis C virus was 1 of 17 tested.
TNM Stage. The pTNM stages of the 41 patients are summarized in Tables 1 and 4 There were no deaths within 6 months after either PHx or OL T. Thereafter, survival after PHx was consistently superior, and, at ') years, the gap was 44% (Fig. 2) . However, because the conditions dictating the use of THx and OL T were different than those for PHx, comparison of survival with these therapeutiC modalities has little value. Of the 18 patiellls who died after the surgical treatment. 16 died from causes related to the tumor occurrences. Two patients, both in the OL T group. died from sepsis
The cumulative survival and the tumor-free survival of the combined cohorts are shown in Fig. 3 Table 7 . The differences III the cUlllulatL\'e survivals and tumor-free survivals among the pT0;M stages were statistically Significant ( Table 7) . rhe lI1i1uence 01 nine clinicopathological Llctors ,1I1 tumorfree and m'l'rall Sllr\"l\'als were examined bv uni\'ariate anah-.,IS (Llbles -+ 'lI1d 5). The invohl'mel1l ,If regional 1\l11ph nodes \" Il. the presence olml'tastasls I ~111. and advancl'd p TNt-.l stage wcre stallsll<.:alh· slgntlic;\I1t prognost IC iactors reducing tUll1or-lree slln·Lvals. ,\Ithough thl'sC Ltctors did not II1dindllalh Illllucnce the o\'l'r'lll "urnval at a '>t;tllsllcalh' slgmlic'Il1L kn'l. sllr\"l\'al of thl' P'tlll'IlLS \\'Ilh st,lge l\'n ""IS slgntilGII1lh' I'l\\l'r (han (haL III thl''>l' \\Ith ,>l.lgC,> II ,lIld III c'LlI11hLl1ed II' '. ll')) \ 15.8 lar invasion of the tumor was a statistically Significant prognostic factor reducing overall survival, but it did not influence tumor-free survivaL Unexpectedly, adjuvant chemotherapy tended to decrease the tumor-free survival (Tables  4 and 5) .
Tumor Recurrence and Treatment
Recurrence of FL-HCC was confirmed in 27 (65.8%) 01 the 41 patients during the stud" period: 18 28 treated with PHx and 9 (69.2%) of the 13 treated with THx and OLT. The time and site of tumor recurrence, treatment used for recurrence, and survival after diagnosis are summarized in Table 8 . The liver was the organ most often involved, followed by the lungs and intra-abdominal lymph nodes.
Attempts at re-resection were made in 6 patients whose original surgery was PHx, and 3 who already had undergone THx and OLT. The secondary surgeries ranged from minor procedures to the drastic step of complete liver replacement in 3 cases, followed by survival of 2, 12, and 30 months ( Table 8) . After the diagnosis of tumor recurrence, the 18 patients initially treated with PHx lived for 1 to 80 months; the 9 first treated with OLT lived for 0 to 43 months. The overall actuarial postrecurrence survival in the combined group (n = 27) at 1,3, and 5 years was 75%, 48%, and 28%, respectively (Fig. 4) . The survival of the 9 patients whose recurrence was treated by surgical resection with or without combined chemotherapy was slightly better than that of the 13 patients who were treated with chemotherapy alone, but the difference was not statistically Significant. One of the 3 long survivors in the IVB group died after 7 years; the other 2 are alive with tumor after 7 and 9 years (PHx 10 and 14) ( Table 9 ). The time of survival postrecurrenee in these unusual cases has been 6.67 and 4.33 years. DISCUSSION FL-HCC was first identified by its unique histological features l and distinctive clinical behavior. I . 7 In our study (see Fig. 1 ), as well as in collected cases from the literature, FL-HCC showed a unimodal age distribution with the peak in the third decade. In contrast. common HCC has a bimodal age distribution when it occurs in the noncirrhotic liver with the peaks in the third and in the sixth decade,29.3o and a unimodal peak in the fifth or sixth decade when cirrhosis is present. 30 The conventional HCC is more frequent in males than females, but the FL-HCC is found almost equally in females (44% in our series). FL-HCC is rarely found in the cirrhotic liver,3.5.9 as was exemplified by only 3 (7.3%) of the 41 cases reported herein.
The tumor markers of FL-HCC have a characteristic pattern. In our series, only 10 .5% of the patients tested had elevated serum a-fetoprotein levels, while the Des-'}'-carboxy prothrombin serum level was elevated in all who were tested. The Des-'}'-carboxy prothrombin level also identified tumor recurrence, whereas the AFP did not. High levels of neurotens in and vitamin B12 binding capacity also have been reported with FL_HCC,II. 13 .31 but these were not determined in our cases.
The indolent growth of FL-HCC and an excellent longterm survival after surgery was first emphaSized by Craig et al. 7 and by Berman et al. H in 1980. based largely on cases collected from the literature. Although Nagorney et al. were the first to question the prognostic SIgnificance of this diagnosis in 1985,2 our report 1 year later+ contained evidence that patients with FL-HCC were excellent candidates for aggressive surgery. Since then, the clinical Significance of a histopathological diagnosis of FL-HCC has been debated among investigators. analyzing small numbers of their own cases in combination with reviews of the literature. Some However, the most important factor obViously was the biological behavior of FL-HCC, the results with which can be compared with our contemporaneous experience with conventional HCC. In patients with HCC in noncirrhotic liver. 5-year global survival was 43.7% after hepatic resection and 26% after transplantation." However, the 5-year survival when the HCC was stage IVA was only 16 .8% after PHx and 10.9% afler OLT,b similar to the experience of others.J2.3A
The indolent growth of FL-HCC was especially obvious when recurrences developed. Even after the diagnOSis of tumor recurrence, survival was 75% at 1 year, 48% at 3 years, and 28% at 5 years (Fig. 4) . Surgical excision of recurrent tumor with or without chemotherapy may have prolonged survival, but, if so, only minimally. Cytoreductive chemotherapy was clearly ineffective. Adjuvant chemotherapy from the outset did not improve survival. However, the impression that it may have been harmful (see Tables 4 and 5 Because of the limited number of cases at stages II and III, a conventional analysis of stratification-specific prognostic factors could not be performed. However, the good results obtained with hepatic resection or transplantation for FL-HCC that was staged at IVA or IVB in >90% of cases can be construed as evidence of the indolent growth, favorable natural behavior, and SUitability for aggressive treatment of these tumors.
In conclusion, the therapeutic approach that we recommend for FL-HCC is wide hepatic resection including the adjacent structures if they are invaded by the tumor. PHx is the treatment of choice if at least one liver segment can be saved. If the presence of underlving liver disease or the location of the tumor preclude PHx, THx with OlT should be consIdered. ,\djuvant chemotherapy so far has not shown anv hendit in patient survival and tumor-free interval. An aggressive surgical approach of tumor recurrences after primary treatment can extend the patient survival.
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